purchase customization

Leave This Empty:

choose chapter to purchase

table of content

Table of Contents
1 Research Methodology and Statistical Scope
1.1 Market Definition and Statistical Scope of Prostate Cancer Nuclear Medicine Diagnostics
1.2 Key Market Segments
1.2.1 Prostate Cancer Nuclear Medicine Diagnostics Segment by Type
1.2.2 Prostate Cancer Nuclear Medicine Diagnostics Segment by Application
1.3 Methodology & Sources of Information
1.3.1 Research Methodology
1.3.2 Research Process
1.3.3 Market Breakdown and Data Triangulation
1.3.4 Base Year
1.3.5 Report Assumptions & Caveats
2 Prostate Cancer Nuclear Medicine Diagnostics Market Overview
2.1 Global Market Overview
2.1.1 Global Prostate Cancer Nuclear Medicine Diagnostics Market Size (M USD) Estimates and Forecasts (2019-2032)
2.1.2 Global Prostate Cancer Nuclear Medicine Diagnostics Sales Estimates and Forecasts (2019-2032)
2.2 Market Segment Executive Summary
2.3 Global Market Size by Region
3 Prostate Cancer Nuclear Medicine Diagnostics Market Competitive Landscape
3.1 Global Prostate Cancer Nuclear Medicine Diagnostics Sales by Manufacturers (2019-2025)
3.2 Global Prostate Cancer Nuclear Medicine Diagnostics Revenue Market Share by Manufacturers (2019-2025)
3.3 Prostate Cancer Nuclear Medicine Diagnostics Market Share by Company Type (Tier 1, Tier 2, and Tier 3)
3.4 Global Prostate Cancer Nuclear Medicine Diagnostics Average Price by Manufacturers (2019-2025)
3.5 Manufacturers Prostate Cancer Nuclear Medicine Diagnostics Sales Sites, Area Served, Product Type
3.6 Prostate Cancer Nuclear Medicine Diagnostics Market Competitive Situation and Trends
3.6.1 Prostate Cancer Nuclear Medicine Diagnostics Market Concentration Rate
3.6.2 Global 5 and 10 Largest Prostate Cancer Nuclear Medicine Diagnostics Players Market Share by Revenue
3.6.3 Mergers & Acquisitions, Expansion
4 Prostate Cancer Nuclear Medicine Diagnostics Industry Chain Analysis
4.1 Prostate Cancer Nuclear Medicine Diagnostics Industry Chain Analysis
4.2 Market Overview of Key Raw Materials
4.3 Midstream Market Analysis
4.4 Downstream Customer Analysis
5 The Development and Dynamics of Prostate Cancer Nuclear Medicine Diagnostics Market
5.1 Key Development Trends
5.2 Driving Factors
5.3 Market Challenges
5.4 Market Restraints
5.5 Industry News
5.5.1 New Product Developments
5.5.2 Mergers & Acquisitions
5.5.3 Expansions
5.5.4 Collaboration/Supply Contracts
5.6 Industry Policies
6 Prostate Cancer Nuclear Medicine Diagnostics Market Segmentation by Type
6.1 Evaluation Matrix of Segment Market Development Potential (Type)
6.2 Global Prostate Cancer Nuclear Medicine Diagnostics Sales Market Share by Type (2019-2025)
6.3 Global Prostate Cancer Nuclear Medicine Diagnostics Market Size Market Share by Type (2019-2025)
6.4 Global Prostate Cancer Nuclear Medicine Diagnostics Price by Type (2019-2025)
7 Prostate Cancer Nuclear Medicine Diagnostics Market Segmentation by Application
7.1 Evaluation Matrix of Segment Market Development Potential (Application)
7.2 Global Prostate Cancer Nuclear Medicine Diagnostics Market Sales by Application (2019-2025)
7.3 Global Prostate Cancer Nuclear Medicine Diagnostics Market Size (M USD) by Application (2019-2025)
7.4 Global Prostate Cancer Nuclear Medicine Diagnostics Sales Growth Rate by Application (2019-2025)
8 Prostate Cancer Nuclear Medicine Diagnostics Market Consumption by Region
8.1 Global Prostate Cancer Nuclear Medicine Diagnostics Sales by Region
8.1.1 Global Prostate Cancer Nuclear Medicine Diagnostics Sales by Region
8.1.2 Global Prostate Cancer Nuclear Medicine Diagnostics Sales Market Share by Region
8.2 North America
8.2.1 North America Prostate Cancer Nuclear Medicine Diagnostics Sales by Country
8.2.2 U.S.
8.2.3 Canada
8.2.4 Mexico
8.3 Europe
8.3.1 Europe Prostate Cancer Nuclear Medicine Diagnostics Sales by Country
8.3.2 Germany
8.3.3 France
8.3.4 U.K.
8.3.5 Italy
8.3.6 Russia
8.4 Asia Pacific
8.4.1 Asia Pacific Prostate Cancer Nuclear Medicine Diagnostics Sales by Region
8.4.2 China
8.4.3 Japan
8.4.4 South Korea
8.4.5 India
8.4.6 Southeast Asia
8.5 South America
8.5.1 South America Prostate Cancer Nuclear Medicine Diagnostics Sales by Country
8.5.2 Brazil
8.5.3 Argentina
8.5.4 Columbia
8.6 Middle East and Africa
8.6.1 Middle East and Africa Prostate Cancer Nuclear Medicine Diagnostics Sales by Region
8.6.2 Saudi Arabia
8.6.3 UAE
8.6.4 Egypt
8.6.5 Nigeria
8.6.6 South Africa
9 Prostate Cancer Nuclear Medicine Diagnostics Market Production by Region
9.1 Global Production of Prostate Cancer Nuclear Medicine Diagnostics by Region (2019-2025)
9.2 Global Prostate Cancer Nuclear Medicine Diagnostics Revenue Market Share by Region (2019-2025)
9.3 Global Prostate Cancer Nuclear Medicine Diagnostics Production, Revenue, Price and Gross Margin (2019-2025)
9.4 North America Prostate Cancer Nuclear Medicine Diagnostics Production
9.4.1 North America Prostate Cancer Nuclear Medicine Diagnostics Production Growth Rate (2019-2025)
9.4.2 North America Prostate Cancer Nuclear Medicine Diagnostics Production, Revenue, Price and Gross Margin (2019-2025)
9.5 Europe Prostate Cancer Nuclear Medicine Diagnostics Production
9.5.1 Europe Prostate Cancer Nuclear Medicine Diagnostics Production Growth Rate (2019-2025)
9.5.2 Europe Prostate Cancer Nuclear Medicine Diagnostics Production, Revenue, Price and Gross Margin (2019-2025)
9.6 Japan Prostate Cancer Nuclear Medicine Diagnostics Production (2019-2025)
9.6.1 Japan Prostate Cancer Nuclear Medicine Diagnostics Production Growth Rate (2019-2025)
9.6.2 Japan Prostate Cancer Nuclear Medicine Diagnostics Production, Revenue, Price and Gross Margin (2019-2025)
9.7 China Prostate Cancer Nuclear Medicine Diagnostics Production (2019-2025)
9.7.1 China Prostate Cancer Nuclear Medicine Diagnostics Production Growth Rate (2019-2025)
9.7.2 China Prostate Cancer Nuclear Medicine Diagnostics Production, Revenue, Price and Gross Margin (2019-2025)
10 Key Companies Profile
10.1 Blue Earth Diagnostics
10.1.1 Blue Earth Diagnostics Prostate Cancer Nuclear Medicine Diagnostics Basic Information
10.1.2 Blue Earth Diagnostics Prostate Cancer Nuclear Medicine Diagnostics Product Overview
10.1.3 Blue Earth Diagnostics Prostate Cancer Nuclear Medicine Diagnostics Product Market Performance
10.1.4 Blue Earth Diagnostics Business Overview
10.1.5 Blue Earth Diagnostics Prostate Cancer Nuclear Medicine Diagnostics SWOT Analysis
10.1.6 Blue Earth Diagnostics Recent Developments
10.2 PETNET Solutions
10.2.1 PETNET Solutions Prostate Cancer Nuclear Medicine Diagnostics Basic Information
10.2.2 PETNET Solutions Prostate Cancer Nuclear Medicine Diagnostics Product Overview
10.2.3 PETNET Solutions Prostate Cancer Nuclear Medicine Diagnostics Product Market Performance
10.2.4 PETNET Solutions Business Overview
10.2.5 PETNET Solutions Prostate Cancer Nuclear Medicine Diagnostics SWOT Analysis
10.2.6 PETNET Solutions Recent Developments
10.3 Cardinal Health
10.3.1 Cardinal Health Prostate Cancer Nuclear Medicine Diagnostics Basic Information
10.3.2 Cardinal Health Prostate Cancer Nuclear Medicine Diagnostics Product Overview
10.3.3 Cardinal Health Prostate Cancer Nuclear Medicine Diagnostics Product Market Performance
10.3.4 Cardinal Health Prostate Cancer Nuclear Medicine Diagnostics SWOT Analysis
10.3.5 Cardinal Health Business Overview
10.3.6 Cardinal Health Recent Developments
10.4 Lantheus Medical Imaging
10.4.1 Lantheus Medical Imaging Prostate Cancer Nuclear Medicine Diagnostics Basic Information
10.4.2 Lantheus Medical Imaging Prostate Cancer Nuclear Medicine Diagnostics Product Overview
10.4.3 Lantheus Medical Imaging Prostate Cancer Nuclear Medicine Diagnostics Product Market Performance
10.4.4 Lantheus Medical Imaging Business Overview
10.4.5 Lantheus Medical Imaging Recent Developments
10.5 Jubilant Pharma
10.5.1 Jubilant Pharma Prostate Cancer Nuclear Medicine Diagnostics Basic Information
10.5.2 Jubilant Pharma Prostate Cancer Nuclear Medicine Diagnostics Product Overview
10.5.3 Jubilant Pharma Prostate Cancer Nuclear Medicine Diagnostics Product Market Performance
10.5.4 Jubilant Pharma Business Overview
10.5.5 Jubilant Pharma Recent Developments
10.6 NCM-USA
10.6.1 NCM-USA Prostate Cancer Nuclear Medicine Diagnostics Basic Information
10.6.2 NCM-USA Prostate Cancer Nuclear Medicine Diagnostics Product Overview
10.6.3 NCM-USA Prostate Cancer Nuclear Medicine Diagnostics Product Market Performance
10.6.4 NCM-USA Business Overview
10.6.5 NCM-USA Recent Developments
10.7 Progenics Pharma
10.7.1 Progenics Pharma Prostate Cancer Nuclear Medicine Diagnostics Basic Information
10.7.2 Progenics Pharma Prostate Cancer Nuclear Medicine Diagnostics Product Overview
10.7.3 Progenics Pharma Prostate Cancer Nuclear Medicine Diagnostics Product Market Performance
10.7.4 Progenics Pharma Business Overview
10.7.5 Progenics Pharma Recent Developments
10.8 Telix Pharma
10.8.1 Telix Pharma Prostate Cancer Nuclear Medicine Diagnostics Basic Information
10.8.2 Telix Pharma Prostate Cancer Nuclear Medicine Diagnostics Product Overview
10.8.3 Telix Pharma Prostate Cancer Nuclear Medicine Diagnostics Product Market Performance
10.8.4 Telix Pharma Business Overview
10.8.5 Telix Pharma Recent Developments
10.9 ImaginAb
10.9.1 ImaginAb Prostate Cancer Nuclear Medicine Diagnostics Basic Information
10.9.2 ImaginAb Prostate Cancer Nuclear Medicine Diagnostics Product Overview
10.9.3 ImaginAb Prostate Cancer Nuclear Medicine Diagnostics Product Market Performance
10.9.4 ImaginAb Business Overview
10.9.5 ImaginAb Recent Developments
10.10 Theragnostics
10.10.1 Theragnostics Prostate Cancer Nuclear Medicine Diagnostics Basic Information
10.10.2 Theragnostics Prostate Cancer Nuclear Medicine Diagnostics Product Overview
10.10.3 Theragnostics Prostate Cancer Nuclear Medicine Diagnostics Product Market Performance
10.10.4 Theragnostics Business Overview
10.10.5 Theragnostics Recent Developments
10.11 Novartis
10.11.1 Novartis Prostate Cancer Nuclear Medicine Diagnostics Basic Information
10.11.2 Novartis Prostate Cancer Nuclear Medicine Diagnostics Product Overview
10.11.3 Novartis Prostate Cancer Nuclear Medicine Diagnostics Product Market Performance
10.11.4 Novartis Business Overview
10.11.5 Novartis Recent Developments
10.12 Alliance Medical
10.12.1 Alliance Medical Prostate Cancer Nuclear Medicine Diagnostics Basic Information
10.12.2 Alliance Medical Prostate Cancer Nuclear Medicine Diagnostics Product Overview
10.12.3 Alliance Medical Prostate Cancer Nuclear Medicine Diagnostics Product Market Performance
10.12.4 Alliance Medical Business Overview
10.12.5 Alliance Medical Recent Developments
11 Prostate Cancer Nuclear Medicine Diagnostics Market Forecast by Region
11.1 Global Prostate Cancer Nuclear Medicine Diagnostics Market Size Forecast
11.2 Global Prostate Cancer Nuclear Medicine Diagnostics Market Forecast by Region
11.2.1 North America Market Size Forecast by Country
11.2.2 Europe Prostate Cancer Nuclear Medicine Diagnostics Market Size Forecast by Country
11.2.3 Asia Pacific Prostate Cancer Nuclear Medicine Diagnostics Market Size Forecast by Region
11.2.4 South America Prostate Cancer Nuclear Medicine Diagnostics Market Size Forecast by Country
11.2.5 Middle East and Africa Forecasted Consumption of Prostate Cancer Nuclear Medicine Diagnostics by Country
12 Forecast Market by Type and by Application (2025-2032)
12.1 Global Prostate Cancer Nuclear Medicine Diagnostics Market Forecast by Type (2025-2032)
12.1.1 Global Forecasted Sales of Prostate Cancer Nuclear Medicine Diagnostics by Type (2025-2032)
12.1.2 Global Prostate Cancer Nuclear Medicine Diagnostics Market Size Forecast by Type (2025-2032)
12.1.3 Global Forecasted Price of Prostate Cancer Nuclear Medicine Diagnostics by Type (2025-2032)
12.2 Global Prostate Cancer Nuclear Medicine Diagnostics Market Forecast by Application (2025-2032)
12.2.1 Global Prostate Cancer Nuclear Medicine Diagnostics Sales (K MT) Forecast by Application
12.2.2 Global Prostate Cancer Nuclear Medicine Diagnostics Market Size (M USD) Forecast by Application (2025-2032)
13 Conclusion and Key Findings